Clinical Trial Update: A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for Syngenon (BSG-001) in inhalation therapy for malignant pleural effusion and malignant ascites across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Ascites
• Malignant Pleural Effusion

Drugs mentioned

• Syngenon (BSG-001)

Snippet

Sponsor: BioSyngen Pte Ltd | Conditions: Malignant Pleural Effusion, Malignant Ascites | Phase 1, Phase 2 | Status: UNKNOWN